CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 5 enrolled
Drug / intervention
INCB099280drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06309394
NCT06309394Phase 1Completed
CompareCT.gov

An Open-Label Study Assessing the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of [14C]INCB099280 in Healthy Male Participants

Incyte Corporation·interventional·Posted Mar 13, 2024·Updated Sep 11, 2025

In Brief

A Phase 1 clinical trial evaluating INCB099280 for Healthy Participants. Completed, enrolled 5 participants across 1 site.

Detailed Summary

This study is being conducted to assess the Mass Balance, Pharmacokinetics, and Metabolite Profiles of a Single Oral Dose of \[14C\]INCB099280 in Healthy Male Participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Participants
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 1CompletedFinished
20252026
First PostedMar 13, 2024
Enrollment StartMay 15, 2024
Primary CompletionJun 4, 2024
TodayJul 2, 2026
Enrollment to primary: 19 daysPosted 2.3 years ago

Interventions

INCB099280drug

INCB099280 will be administered orally, followed approximately 10 minutes later by an oral dose solution of radiolabeled INCB099280.